CareDx, Inc. (CDNA)

Over the past six months, CareDx's stock price has experienced fluctuations, with a closing stock price of $14.97 as of October 24, 2025. Key events impacting the stock include a financial turnaround reported in February 2025, earnings results announced in August 2025, target price adjustments by Wells Fargo & Company, initiation of coverage by William Blair, reissuance of a buy rating by BTIG Research, upgrade of stock rating by Wall Street Zen, publication of a landmark study on antibody-mediated rejection in heart transplantation, appointment of Suresh Gunasekaran to its Board of Directors, and the scheduled report of its Third Quarter 2025 financial results on November 4, 2025.

The provided information does not explicitly mention any demand seasonality for CareDx, Inc.'s products and services.

CareDx, Inc. is a precision medicine company focused on developing and commercializing healthcare solutions for transplant patients and caregivers, operating in the Healthcare sector, specifically in the Diagnostics & Research industry. Its core business revolves around providing genomics-based information and diagnostic surveillance solutions for transplant patients, with major products and services including AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung. The company also offers a lab product portfolio that includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA, and provides a diverse portfolio of digital solutions to transplant centers.

CareDx, Inc. generates the majority of its revenue from the United States and engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers both in the United States and internationally. Its corporate office is located in Brisbane, California, United States.

CareDx maintains a reputation as a company committed to social responsibility and ethical governance, actively participating in shaping public policy for transplant patients, providing education and training to healthcare professionals, and is involved in the scientific community through clinical trials and medical conferences. Its main buildings are energy efficiency certified, and several offices are in LEED-certified buildings, demonstrating an environmental commitment. CareDx also invests significantly in research and development to advance transplant innovation.

CareDx, Inc. has 496 institutional owners and shareholders holding a total of 71,226,272 shares, with approximately 47.85% of the company's stock owned by Institutional Investors, 9.19% by Insiders, and 42.96% by Public Companies and Individual Investors. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and Invesco Ltd., with VANGUARD INDEX FUNDS owning the most shares.